Plain-English translation of NCT07161999 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help slow down ALS progression. The medication works by calming excessive inflammation in the nervous system—it enhances the body's natural anti-inflammatory cells while reducing harmful inflammation-causing cells. Participants will receive this treatment or a placebo (inactive substance) for 24 weeks, then those who complete that phase may continue with the actual medication for another 24 weeks.
ALS is a disease where nerve cells gradually die, causing progressive muscle weakness and loss of function. Researchers believe that inflammation plays a major role in this damage. This trial is testing whether this new two-part treatment can reduce that harmful inflammation and slow disease progression.
You will visit one of 20–25 study sites across the US and Canada. During the first 24 weeks, you will receive either the new medication or a placebo as 5 daily subcutaneous injections (under the skin) every other week in a specific pattern. Researchers will assess your ALS progression using standard clinical tests, blood work, and breathing measurements. If you complete the first phase, you can continue for another 24 weeks receiving the actual medication.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States